Abstract
The Monogenic Network of the Global Parkinson’s Genetics Program (GP2) aims to create an efficient infrastructure to accelerate the identification of novel genetic causes of Parkinson’s disease (PD) and to improve our understanding of already identified genetic causes, such as reduced penetrance and variable clinical expressivity of known disease-causing variants. We aim to perform short- and long-read whole-genome sequencing for up to 10,000 patients with parkinsonism. Important features of this project are global involvement and focusing on historically underrepresented populations.
| Original language | English (US) |
|---|---|
| Article number | 100 |
| Journal | npj Parkinson's Disease |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 2023 |
Funding
C.K. has received grant support from the Michael J. Fox Foundation for Parkinson’s Research and the Aligning Science Across Parkinson’s Initiative. She serves as a medical advisor to Centogene and Retromer Therapeutics and has received a speaker’s honorarium from Desitin Pharma. S.-Y.L. received grants from the Michael J. Fox Foundation and the Malaysian Ministry of Education Fundamental Research Grant Scheme. A.S. and C.B. have received grant support from the Michael J. Fox Foundation for Parkinson’s Research and the Aligning Science Across Parkinson’s Initiative. A.S. has received royalty payments related to a diagnostic for stroke. M.N. is a consultant employed by Data Tecnica International. Data Tecnica is engaged in a consulting agreement with the US National Institutes of Health. A.S. and K.L. are editors for npj Parkinson’s Disease. A.S. and K.L. were not involved in the journal’s review of, or decisions related to, this manuscript. L.M.L., M.A., M.E., Z.-H.F., C.G., P.H., A.I., J.J., I.J.K.S., K.R.K., H.M., N.M., K.R., A.-H.T., E.M.V., J.S., and C.W. declare no competing interests. This research is supported by the Aligning Science Across Parkinson’s Initiative and the Michael J. Fox Foundation for Parkinson’s Research. Data Code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Against Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research ( https://gp2.org ). For a complete list of GP2 members see https://gp2.org . A. Singleton and C. Blauwendraat are supported by the Intramural Research Program of the National Institute on Aging.
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
- Cellular and Molecular Neuroscience